OakChart

Viridian Therapeutics Inc

VRDNHealthcare·Biotechnology·USA·Mid·NASD·Nov 11 • 10:57 AM ET

30.85-0.01 (-0.03%)
2026-11-11 16:57 CET
Market cap
3,504.40 USD m
Revenue, TTM
26.31 USD m
Net income, TTM
-435.21 USD m
Free cash flow, TTM
-343.92 USD m
EPS diluted, TTM
-4.18
P/E
-
Compare

Price

VRDN against its 20, 50 and 200-day averages
2050200beatmiss
15.0020.0025.0030.005.6M11.2MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26VRDNclose 30.8520-day 24.9850-day 22.43200-day 21.5830.85

10.0% under the 52-week high of 34.29 on 14 Jan 2026. 52-week low 13.18 on 29 Apr 2026. Last 15 sessions, 41.5% high to low

Profile

VRDN
52-week range, 84% of the way up
13.1834.29

Viridian Therapeutics, Inc. is a biopharmaceutical company that develops medicines for autoimmune and rare diseases. It uses antibody discovery and protein engineering to create new therapies. The company is advancing late-stage IGF-1R therapies for thyroid eye disease (TED) and developing a potential TSHR-targeted treatment for TED and Graves' disease. In addition, it is developing FcRn inhibitors, including VRDN-006 and VRDN-008, for multiple autoimmune diseases. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

IndexRUT
Employees252
IPOJun 18, 2014
Beta1.04
ATR, 14d1.35
Rel volume0.56
Short float15.99%
Insider own6.12%
Inst own117.93%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap3.50B
Enterprise Value2.89B
Income-435.21M
Sales26.31M
Book/sh4.25
Cash/sh8.42
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees252
IPOJun 18, 2014

Ratios

P/E-
Forward P/E-
PEG-
P/S133.15
P/B7.26
P/C3.66
P/FCF-
EV/EBITDA-
EV/Sales109.77
Quick Ratio14.46
Current Ratio14.46
Debt/Eq0.42
LT Debt/Eq0.42
Option/ShortYes / Yes

Earnings

EPS (ttm)-4.18
EPS next Y-2.09
EPS next Q-0.72
EPS this Y-6.90%
EPS next Y41.07%
EPS next 5Y-
EPS past 3/5Y6.35% 36.07%
Sales past 3/5Y241.95% 132.18%
EPS Y/Y TTM-18.22%
Sales Y/Y TTM-62.83%
EPS Q/Q-110.97%
Sales Q/Q-63.51%
EarningsNov 04 BMO
EPS/Sales Surpr.20.22% 445.10%

Ownership

Insider Own6.12%
Insider Trans20.08%
Inst Own117.93%
Inst Trans10.11%
ROA-54.20%
ROE-80.32%
ROIC-52.87%
Gross Margin90.77%
Oper. Margin-1781.38%
Profit Margin-1654.21%
SMA2023.49%
SMA5037.56%
SMA20042.94%
Trades-

Technical

Shs Outstand113.53M
Shs Float106.61M
Short Float15.99%
Short Ratio8.19
Short Interest17.04M
52W High34.29 -10.03%
52W Low13.18 134.07%
Volatility8.12% 5.77%
ATR (14)1.35
RSI (14)81.69
Beta1.04
Rel Volume0.56
Avg Volume2.08M
Volume304,413

Performance

Perf Week6.18%
Perf Month69.32%
Perf Quarter40.29%
Perf Half Y81.04%
Perf YTD-0.87%
Perf Year8.51%
Perf 3Y124.20%
Perf 5Y67.39%
Perf 10Y-62.12%
Recom1.00
Target Price42.50
Prev Close30.86
Price30.85
Change %-0.03%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Jun 29, 2026UpgradeWWells FargoEqual Weight → Overweight$31+0.5%
Dec 10, 2025ReiteratedWWedbushOutperform$42 → $47+52.4%
Dec 03, 2025InitiatedWWilliam BlairOutperform
Nov 24, 2025InitiatedTTruistBuy
Aug 25, 2025ResumedJJefferiesBuy$44+42.6%
Dec 19, 2024DowngradeWWells FargoOverweight → Equal Weight$37 → $27-12.5%
Nov 25, 2024InitiatedTTD CowenBuy
Sep 11, 2024ReiteratedNNeedhamBuy$30 → $38+23.2%
Jun 11, 2024InitiatedWWolfe ResearchOutperform$29-6.0%
Jun 06, 2024InitiatedGGoldmanBuy$23-25.4%

Peers

Mkt cap
TickerCompanyMkt cap
IMVTImmunovant Inc7.61B
YARWYarrow Bioscience Inc174.04M
ARGXArgen X SE ADR60.88B
DNTHDianthus Therapeutics Inc5.05B
ZBIOZenas Biopharma Inc1.95B
ANABAnaptysBio Inc1.46B
CLYMClimb Bio Inc706.92M
AUPHAurinia Pharmaceuticals Inc2.16B
MLTXMoonLake Immunotherapeutics1.14B
TRVITrevi Therapeutics Inc2.11B

Insider trading

11 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Tousignant JenniferChief Legal OfficerAug 19 '26Option Exercise14.4110,000144,10010,000Aug 20 08:05 PM
Tousignant JenniferChief Legal OfficerAug 19 '26Sale24.5014,212348,1940Aug 20 08:05 PM
Tousignant JenniferOfficerAug 19 '26Proposed Sale24.5014,212348,194Aug 19 02:30 PM
Tripuraneni RadhikaChief Medical OfficerAug 14 '26Option Exercise13.2140,000528,40040,000Aug 18 05:34 PM
Fairmount Funds Management LLCDirectorMay 11 '26Buy17.001,176,47019,999,9905,090,928May 13 04:31 PM
Beetham Thomas W.OfficerMar 04 '26Proposed Sale30.193,04892,004Mar 04 04:29 PM
Tousignant JenniferOfficerMar 04 '26Proposed Sale30.191,67550,560Mar 04 04:25 PM
Harmon SethOfficerMar 04 '26Proposed Sale30.192,03161,306Mar 04 04:20 PM
Mahoney Stephen F.OfficerMar 04 '26Proposed Sale30.197,408223,610Mar 04 04:10 PM
Tousignant JenniferChief Legal OfficerDec 31 '25Sale31.162,27270,7960Jan 02 05:25 PM
Tousignant JenniferOfficerDec 31 '25Proposed Sale31.162,27270,796Dec 31 12:24 PM

Held by

AUM
TickerCompanyAUM
IWMiShares Russell 2000 Index FundAUM: 77.38B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
DFASU.S. Small Cap Portfolio-ETF Class Shares-
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWCiShares Micro-Cap ETFAUM: 1.22B
DFACU.S. Core Equity 2 Portfolio-ETF Class Shares-

News

latest 14 of 206
  • Viridian Therapeutics gains long-term potential from extended-acting FcRn drug, Jefferies says (Proactive) +5.97%
  • Viridian Therapeutics Announces Positive VRDN-008 Phase 1 Results Supporting Potential Best-in-Class Profile with Every-8-Week Subcutaneous Dosing (Business Wire)
  • Viridian Therapeutics to Host Conference Call to Present VRDN-008 Phase 1 Data and FcRn Portfolio Plans on November 9, 2026 (Business Wire)
  • Viridian's Lumvoa Launch Crushes Revenue Expectations, But Thin Disclosure Leaves Durability Questions Open (Earnings Whispers) +15.53%
  • Viridian Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Business Progress (Business Wire)
  • Loading…
  • Viridian's Q3 Loss Should Hold Near $1 A Share; Cash And VRDN-001 Progress Matter More (Earnings Whispers)
  • Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026 (Business Wire) +7.84%
  • Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference (Business Wire)
  • Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results (Business Wire) +6.83%
  • Viridian may have edge over Amgen in eye drug showdown, analysts argue (BioPharma Dive)
  • Comcast, Viridian Therapeutics jump premarket; Doximity slips (Investing.com)
  • VRDN Stock Jumps 6% After-Hours As Viridian Wins First FDA Approval (Stocktwits)
  • Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa (veligrotug-vvze) for the Treatment of Thyroid Eye Disease (Business Wire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-04-0.810-1.015-0.81025.754.7214
2026Q22026-08-06-1.050-1.035-1.1780.280.0614
2026Q12026-05-05-0.900-1.081-1.0260.140.0414
2025Q42026-02-26-1.080-0.980-1.0810.1318.3816
2025Q32025-11-05-0.340-1.019-0.42370.570.0314
2025Q22025-08-06-1.000-1.009-1.2350.080.0515
2025Q12025-05-06-0.870-0.967-1.0680.070.0514
2024Q42025-02-27-0.810-1.035-0.8080.070.0415
2024Q32024-11-12-1.150-1.057-1.1550.090.0814
2024Q22024-08-08-1.020-0.871-1.0180.070.0815
2024Q12024-05-08-0.790-1.089-0.7950.070.0913
2023Q42024-02-27-1.350-0.978-1.3460.070.1513
2023Q32023-11-13-1.090-1.245-1.0920.070.1514
2023Q22023-08-08-1.270-1.261-1.2730.070.2514
2023Q12023-05-09-1.610-1.011-1.6130.100.1210
2022Q42023-03-08-1.130-0.728-1.1290.110.4610

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-20.100-17.130-20.0444.464.32
2020FY-31.130-5.112-31.1251.050.87
2021FY-6.680-5.384-6.6632.963.00
2022FY-4.050-3.557-4.0481.772.13
2023FY-5.310-4.937-5.3120.310.37
2024FY-3.770-4.001-3.0720.300.32
2025FY-3.320-3.531-4.04070.8585.43
2026FY--3.549--75.13
2027FY--2.092--314.19
2028FY-0.188--678.27
2029FY-1.957--976.98
2030FY-3.569--1,295

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-061413149.0730.9171.30
2026Q4S2026-11-041413046.7214.4071.31
2026Q4S2026-11-03141219.169.0533.82
2026Q4S2026-10-26141219.179.0534.00
2026Q4S2026-10-16141119.309.0534.00
2026Q4S2026-10-15141119.289.0533.82
2026Q4S2026-10-13141119.299.0533.82
2026Q4S2026-09-21141019.719.0533.82
2026Q4S2026-09-12140018.119.0533.82
2026Q4S2026-09-09140118.119.0533.82
2026Q4S2026-08-06143718.119.0533.82
2026Q4S2026-07-29143718.119.0533.82
2026Q4S2026-07-19143718.119.0533.82
2026Q4S2026-07-01143818.119.0533.82

Estimate history

EPS, annual-20.7-16.572-20.044-31.125-6.663-4.048-5.312-3.072-3.325-4.1776
Period201720182019202020212022202320242025TTM
EPS, quarterly-1.155-0.808-1.068-1.235-0.423-1.081-1.026-1.178-0.892
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual4.0038.3864.4611.052.9631.7720.3140.30270.84926.31
Period201720182019202020212022202320242025TTM
Sales, quarterly0.0860.0720.0720.07570.570.1320.1410.28425.752
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual1.5052.0562.3244.23123.92441.30653.98680.994101.827113.525
Period201720182019202020212022202320242025MRQ
Shares, quarterly79.18180.99481.58981.65182.229101.827102.458113.238113.525
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue26.3170.850.300.311.772.961.054.468.39
Cost of Goods Sold Incl. D&A2.431.161.241.320.760.62---
Gross Profit23.8869.69-0.94-1.011.022.34---
Selling, General and Administrative Excl. Other492.54433.08298.10253.44135.3282.0740.7346.1541.19
Research and Development307.81338.47237.71159.24100.6456.7727.7734.5130.42
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-468.66-363.39-299.04-254.45-134.30-79.73-40.22-41.98-33.08
Interest Expense24.324.953.051.850.490.000.510.830.87
Unusual Expense-7.710.700.000.200.000.0070.16--
Net Income Before Taxes-453.58-342.60-269.95-237.73-129.87-79.41-110.72-41.87-32.70
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-435.21-281.93-208.56-237.73-129.87-79.41-110.72-41.87-32.70
Net Income From Continuing Operations-435.21-281.93-208.56-237.73-129.87-79.41-110.72-41.87-32.70
Net Income-435.21-281.93-208.56-237.73-129.87-79.41-110.72-41.87-32.70
EPS (Recurring)-3.89-3.32-3.07-5.31-4.05-6.66-17.32-20.04-16.57
EPS (Basic, Before Extraordinaries)-4.18-3.32-3.07-5.31-4.05-6.66-31.13-20.04-16.57
EPS (Diluted)-4.18-3.32-3.07-5.31-4.05-6.66-31.13-20.04-16.57
EBITDA-467.76-362.24-297.80-253.13-133.55-79.11-39.68-41.69-32.80
Non-Operating Income (Expense)31.6926.4432.1318.764.920.320.170.941.25
Other After Tax Adjustments18.3860.6761.390.000.000.000.000.000.00
Stock Option Compensation Expense59.5944.3042.1567.1719.7714.463.653.973.68
Price To Sales Ratio88.7637.254,309.183,104.38528.9379.5355.733.3710.70
Gross Margin90.7798.36-310.60-321.0257.3979.08---
Operating Margin-1,781.38-512.91-99,018.21-81,035.03-7,579.23-2,690.79-3,830.38-941.02-394.51
Net Margin-1,654.21-397.93-69,059.60-75,711.46-7,329.23-2,680.16-10,544.29-938.65-389.97
Shares Outstanding113.53101.8380.9953.9941.3123.924.232.322.06
Market Capitalization3,504.403,504.401,518.511,145.321,175.65429.4564.2916.7393.44

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue25.750.280.140.1370.570.070.070.07
Cost of Goods Sold Incl. D&A1.870.120.120.320.310.310.320.12
Gross Profit23.880.170.02-0.1970.26-0.24-0.24-0.05
Selling, General and Administrative Excl. Other127.36126.44116.19122.56110.27106.5393.6287.42
Research and Development69.7571.4677.5189.0986.1586.5176.7271.84
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-103.48-126.27-116.17-122.75-40.01-106.77-93.87-87.47
Interest Expense9.278.313.463.280.560.510.590.86
Unusual Expense-2.071.19-7.530.700.000.000.000.00
Net Income Before Taxes-101.21-127.12-104.90-120.36-34.60-100.73-86.91-79.72
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-101.21-127.12-104.90-101.98-34.60-100.73-86.91-64.65
Net Income From Continuing Operations-101.21-127.12-104.90-101.98-34.60-100.73-86.91-64.65
Net Income-101.21-127.12-104.90-101.98-34.60-100.73-86.91-64.65
EPS (Recurring)-0.91-1.17-1.08-1.08-0.42-1.23-1.07-0.81
EPS (Basic, Before Extraordinaries)-0.89-1.18-1.03-1.08-0.42-1.23-1.07-0.81
EPS (Diluted)-0.89-1.18-1.03-1.08-0.42-1.23-1.07-0.81
EBITDA-103.13-126.15-116.05-122.43-39.70-106.45-93.55-87.35
Non-Operating Income (Expense)9.478.657.206.385.976.557.548.61
Other After Tax Adjustments0.000.000.0018.380.000.000.0015.08
Stock Option Compensation Expense17.2316.9813.3911.9911.2510.8410.228.97
Price To Sales Ratio88.7627.8628.1941.4524.933,739.923,630.865,081.45
Gross Margin92.7458.8014.18-142.4299.56-317.33-340.28-70.83
Operating Margin-401.82-44,460.56-82,389.36-92,991.67-56.70-142,356.00-130,369.44-121,488.89
Net Margin-393.01-44,760.21-74,397.87-77,256.06-49.03-134,313.33-120,711.11-89,788.89
Shares Outstanding113.53113.24102.46101.8382.2381.6581.5980.99
Market Capitalization3,504.402,028.561,999.172,970.161,762.271,140.661,098.421,518.51

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments874.65717.58477.37424.55196.97127.6426.8462.4847.44
Short Term Receivables0.000.000.100.100.450.000.110.021.46
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets19.5820.889.016.522.751.972.792.872.97
Total Current Assets894.23738.46486.48431.17200.16129.6129.7465.3751.87
Net Property, Plant & Equipment3.653.443.342.942.060.790.520.730.56
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets------0.00-0.00
Other Assets1.540.500.600.981.490.860.000.050.05
Total Assets899.42742.40490.42435.09203.71131.2530.2666.1552.48
Short Term Debt Incl. Current Port. of LT Debt0.750.510.840.610.520.463.982.290.00
Accounts Payable8.682.142.2414.232.330.671.100.570.91
Other Current Liabilities61.2645.2223.5518.5010.799.555.113.872.99
Total Current Liabilities70.7047.8726.6433.3513.6410.6710.186.733.90
Long Term Debt49.9422.5821.205.750.520.044.338.009.92
Provision for Risks Charges34.240.000.000.000.000.000.000.000.00
Other Liabilities22.370.310.560.931.840.500.000.070.15
Total Liabilities177.2570.7648.4040.0315.9911.2214.5114.8013.97
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value132.06188.88206.52142.15133.83180.800.000.000.00
Common Equity590.11482.75235.51252.9253.88-60.7615.7551.3438.51
Total Shareholders Equity722.17671.64442.02395.06187.72120.0415.7551.3438.51
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity722.17671.64442.02395.06187.72120.0415.7551.3438.51
Total Liabilities & Stockholders Equity899.42742.40490.42435.09203.71131.2530.2666.1552.48
Book Value Per Share5.805.964.366.122.25-14.366.7824.9725.60
Tangible Book Value Per Share5.805.964.366.122.25-14.366.7824.9725.60
Full-Time Employees25214396865027468065
Price to Book Ratio7.262.936.402.878.78-1.151.061.825.86
Return on Assets-34.34-33.83-51.37-40.66-47.42-137.09-86.87-55.14-93.47
Return on Equity-40.45-37.45-56.80-44.57-51.61-163.07-124.81-72.79-138.89
Return on Invested Capital-36.51-30.04-51.32-32.40-42.19-92.20-208.51-55.10-54.75
Quick Ratio12.6515.4318.2612.9314.6812.142.929.7113.31
Current Ratio12.6515.4318.2612.9314.6812.142.929.7113.31

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-453.58-342.60-269.95-237.73-129.87-79.41-110.72-41.87-32.70
Depreciation0.700.460.541.320.760.620.240.290.28
Other Funds (Non Cash)66.5442.2427.4961.6719.3222.4976.273.883.64
Funds from Operations-386.34-299.90-241.92-174.75-109.80-56.30-34.21-37.71-28.78
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital44.3623.039.60-9.4315.961.724.431.651.94
Cash from Operating Activities-341.98-276.87-232.32-184.17-93.84-54.58-29.78-36.06-26.84
Capital Expenditures-1.94-0.49-0.51-0.90-0.80-0.34-0.04-0.08-0.45
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.0829.370.000.00
Purchase or Sale of Investments-457.04-37.07-228.14-93.35-114.33-74.03-79.8128.31-29.46
Purchase of Investments-1,083.79-579.28-695.07-407.88-223.26-188.43-81.81-32.69-62.46
Sale Or Maturity of Investments626.75542.21466.93314.53108.94114.402.0061.0033.00
Other Uses-10.000.000.000.000.000.00-0.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-468.98-37.56-228.65-94.25-115.13-74.29-50.4828.23-29.91
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock474.30348.33457.74211.18317.69125.28109.922.4041.92
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00-2.96
Sale of Common Pref Stock474.30348.33457.74211.18317.69125.28109.922.4044.87
Proceedsfrom Stock Options470.19333.54451.72190.04313.99123.9984.822.3244.45
Issuance or Reduction of Debt, Net216.1628.880.0014.494.550.00-8.57-2.330.00
Change in Long Term Debt216.1628.880.0014.494.550.00-8.57-2.330.00
Issuance of Long Term Debt270.8628.880.0014.494.550.001.730.000.00
Reduction of Long Term Debt-54.700.000.000.000.000.00-10.29-2.330.00
Net Financing Active Other Cash Flow125.0250.020.000.000.000.00-0.040.000.00
Other Financing Activities Uses-4.98-4.980.000.000.000.00-0.040.000.00
Cash from Financing Activities815.48427.22457.74225.67322.24125.28101.310.0741.92
Net Change in Cash4.51112.79-3.23-52.75113.28-3.6021.05-7.76-14.84
Free Cash Flow-343.92-277.36-232.83-185.07-94.64-54.92-29.82-36.14-27.29
Preferred Dividends (Cash Flow)-------0.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments956.51981.53762.18874.65490.90563.36
Short Term Receivables29.7875.000.000.0070.000.00
Inventories0.090.000.000.000.000.00
Other Current Assets26.7624.7422.5619.5811.0115.39
Total Current Assets1,013.131,081.27784.74894.23571.91578.75
Net Property, Plant & Equipment5.624.853.383.653.713.07
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets9.7910.00----
Other Assets0.131.110.891.541.520.51
Total Assets1,028.671,097.23789.02899.42577.14582.32
Short Term Debt Incl. Current Port. of LT Debt0.810.720.740.750.738.99
Accounts Payable9.308.6513.318.6810.068.52
Other Current Liabilities59.9554.4237.7561.2639.9035.08
Total Current Liabilities70.0563.7951.8070.7050.7052.59
Long Term Debt242.46242.1650.4449.9423.0914.05
Provision for Risks Charges121.61113.6436.0934.240.000.00
Other Liabilities13.8515.5414.6822.370.380.52
Total Liabilities447.97435.14153.01177.2574.1767.16
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value98.0298.02132.06132.06188.88188.88
Common Equity482.67564.07503.95590.11314.08326.28
Total Shareholders Equity580.70662.10636.01722.17502.97515.17
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity580.70662.10636.01722.17502.97515.17
Total Liabilities & Stockholders Equity1,028.671,097.23789.02899.42577.14582.32
Book Value Per Share4.254.984.925.803.824.00
Tangible Book Value Per Share4.174.894.925.803.824.00
Full-Time Employees---252--
Price to Book Ratio7.263.733.388.155.402.74
Return on Assets-54.20-43.89-47.20-39.50-42.53-56.33
Return on Equity-80.32-62.62-55.17-46.52-47.40-62.99
Return on Invested Capital-12.30-14.06-15.28-13.21-6.58-19.03
Quick Ratio14.4616.9515.1512.6511.2811.01
Current Ratio14.4616.9515.1512.6511.2811.01

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-101.21-127.12-104.90-120.36-34.60-100.73
Depreciation0.340.120.120.120.110.11
Other Funds (Non Cash)21.8623.516.5214.6510.219.38
Funds from Operations-79.01-103.49-98.26-105.58-24.28-91.24
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-13.76-1.83-21.3981.35-60.3315.87
Cash from Operating Activities-92.77-105.32-119.65-24.23-84.61-75.37
Capital Expenditures-0.37-1.31-0.02-0.24-0.13-0.04
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments34.71-229.8577.28-339.18126.2075.76
Purchase of Investments-175.62-378.65-91.32-438.19-14.09-55.76
Sale Or Maturity of Investments210.33148.80168.6099.01140.29131.51
Other Uses-10.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities24.34-231.1677.26-339.42126.0875.72
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.00---0.00-
Change in Capital Stock3.12137.336.36327.4910.860.76
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock3.12137.336.36327.4910.860.76
Proceedsfrom Stock Options-7.44137.336.36333.95-5.150.00
Issuance or Reduction of Debt, Net-0.51187.790.0028.880.000.00
Change in Long Term Debt-0.51187.790.0028.880.000.00
Issuance of Long Term Debt-0.51242.490.0028.880.000.00
Reduction of Long Term Debt0.00-54.700.000.000.000.00
Net Financing Active Other Cash Flow75.000.000.0050.020.000.00
Other Financing Activities Uses0.000.000.00-4.980.000.00
Cash from Financing Activities77.61325.126.36406.3910.860.76
Net Change in Cash9.17-11.36-36.0442.7352.321.11
Free Cash Flow-93.14-106.63-119.68-24.47-84.74-75.42

Revenue breakdown

Collaboration2024: 302.00K 2025: 849.00K
License2025: 70.00M
United States2024: 302.00K 2025: 70.85M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3015.99%17.0M106.6M1.80M
2026-10-1516.93%18.0M106.4M1.78M
2026-09-3016.89%18.0M106.4M1.72M
2026-09-1518.30%19.5M106.4M1.89M
2026-08-3118.35%19.5M106.4M1.92M
2026-08-1417.89%19.0M106.4M2.04M
2026-07-3118.29%19.2M105.2M2.52M
2026-07-1518.46%18.9M102.5M2.52M
2026-06-3016.74%17.3M103.6M2.91M
2026-06-1514.66%15.0M102.5M2.82M
2026-05-2914.24%14.6M102.5M2.79M
2026-05-1513.92%14.3M102.5M2.73M
2026-04-3012.21%11.5M94.3M2.14M
2026-04-1511.40%10.7M93.5M2.11M
2026-03-3111.78%10.8M92.1M1.69M
2026-03-138.94%8.2M92.1M1.44M
2026-02-278.49%7.8M92.1M1.46M
2026-02-139.03%7.8M86.0M1.55M
2026-01-309.23%7.9M86.0M1.63M
2026-01-159.48%8.1M86.0M1.70M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call10.0018.8022.800.008.2380.000.000.951-0.1630.005
call13.0015.8019.800.006.5330.000.000.936-0.1610.006
call14.0014.7018.800.006.0710.000.000.930-0.1590.006
call15.0013.7017.805.005.6482.000.000.924-0.1570.007
call16.0012.7016.800.005.2550.000.000.918-0.1550.007
call17.0011.7015.806.204.8902.000.000.911-0.1520.008
call18.0010.7014.807.004.5471.000.000.904-0.1500.008
call19.009.7013.8010.674.22317.000.000.895-0.1470.009
call20.008.7012.801.913.91679.000.000.887-0.1430.009
call21.007.8011.802.003.62331.000.000.877-0.1390.010
call22.006.7010.807.203.34224.000.000.865-0.1350.011
call23.005.809.806.203.0721380.000.853-0.1300.011
call24.004.708.801.952.71613.000.000.839-0.1260.012
call25.005.206.905.151.23388.003.000.821-0.1200.013
call26.002.655.204.001.0651340.000.801-0.1130.014
call27.002.405.802.051.59018.000.000.776-0.1060.015
call28.001.504.601.501.6085270.000.739-0.0990.016
call29.000.704.700.651.9352.000.000.640-0.2800.018
call30.001.102.951.551.3224780.000.599-0.2280.019
call31.000.404.700.851.5701.000.000.554-0.2090.019
call32.000.054.700.001.7850.000.000.508-0.2020.019
call33.000.004.700.001.9870.000.000.471-0.2090.019
call34.000.004.800.002.1450.000.000.453-0.2290.019
call35.000.004.700.502.3117.000.000.434-0.2440.019
call36.000.004.700.002.4490.000.000.419-0.2580.019
call37.000.004.800.002.5990.000.000.405-0.2710.019
call38.000.004.700.002.7240.000.000.394-0.2820.019
call39.000.001.650.002.1290.000.000.298-0.1980.017
call40.000.004.800.002.2400.000.000.288-0.2060.017
call41.000.003.500.002.3400.000.000.280-0.2120.016
put10.000.004.800.156.0271.000.00-0.049-0.1620.005
put13.000.004.700.304.7695.000.00-0.064-0.1590.006
put14.000.004.700.354.4194.000.00-0.070-0.1580.006
put15.000.004.700.554.0971.000.00-0.076-0.1560.007
put16.000.004.700.003.7970.000.00-0.082-0.1530.007
put17.000.004.700.003.5150.000.00-0.089-0.1510.008
put18.000.004.700.003.2490.000.00-0.096-0.1480.008
put19.000.004.700.502.9954.000.00-0.105-0.1440.009
put20.000.004.801.682.75643.000.00-0.113-0.1410.009
put21.000.004.700.052.5369.000.00-0.123-0.1380.010
put22.000.004.702.802.3182.000.00-0.134-0.1330.010
put23.000.004.700.152.0891610.00-0.147-0.1280.011
put24.000.001.654.501.8911.000.00-0.161-0.1230.012
put25.000.004.705.101.6871.000.00-0.179-0.1170.013
put26.000.004.800.001.4860.000.00-0.199-0.1100.014
put27.000.004.700.001.2910.000.00-0.224-0.1030.015
put28.000.000.900.001.0790.000.00-0.264-0.0960.016
put29.000.054.700.002.9910.000.00-0.360-0.2760.018
put30.000.054.709.902.6922.000.00-0.401-0.2250.019
put31.000.354.700.002.3900.000.00-0.446-0.2050.019
put32.001.004.700.002.0810.000.00-0.492-0.1980.019
put33.000.704.700.001.7750.000.00-0.526-0.2040.019
put34.001.605.800.001.9760.000.00-0.548-0.2260.019
put35.002.106.300.001.8700.000.00-0.566-0.2410.019
put36.003.207.300.002.0240.000.00-0.582-0.2550.019
put37.004.208.300.002.0990.000.00-0.596-0.2680.019
put38.005.209.300.002.3230.000.00-0.604-0.2820.019
put39.006.2010.300.002.4460.000.00-0.699-0.1980.017
put40.007.2011.300.002.5620.000.00-0.708-0.2050.017
put41.008.2012.300.002.6720.000.00-0.717-0.2120.016

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10SCHEDULE 13GSEC
2026-11-098-KCurrent report2026-11-09SEC
2026-11-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-048-KCurrent report2026-11-04SEC
2026-08-204Statement of changes in beneficial ownership of securities2026-08-19SEC
2026-08-20SCHEDULE 13GSEC
2026-08-19144Filing for proposed sale of securities under Rule 144.SEC
2026-08-184Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13GSEC
2026-08-07SCHEDULE 13GSEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-06-298-KCurrent report2026-06-26SEC
2026-06-26SCHEDULE 13GSEC
2026-06-038-KCurrent report2026-06-02SEC
2026-05-288-KCurrent report2026-05-27SEC
2026-05-268-KCurrent report2026-05-24SEC
2026-05-15SCHEDULE 13GSEC
2026-05-134Statement of changes in beneficial ownership of securities2026-05-11SEC
2026-05-13SCHEDULE 13D/ASEC
2026-05-118-KCurrent report2026-05-06SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-0800348.19K1
2026-070000
2026-060000
2026-0520.00M100
2026-040000
2026-030000
2026-020000
2026-010000
2025-120070.80K1
2025-110000

Institutional holders

Manager% owned
FMR LLC15.45%
BlackRock, Inc.7.74%
Bellevue Group AG6.10%
Paradigm Biocapital Advisors LP6.09%
Kynam Capital Management, LP5.84%
STATE STREET CORP5.55%
PRICE T ROWE ASSOCIATES INC /MD/5.21%
Fairmount Funds Management LLC4.61%
VANGUARD CAPITAL MANAGEMENT LLC4.14%
Deep Track Capital, LP3.25%

Funds

Fund% owned
State Street(R) SPDR(R) S&P(R) Biotech ETF3.55%
VANGUARD TOTAL STOCK MARKET INDEX FUND3.02%
iShares Russell 2000 ETF2.13%
Fidelity Advisor Biotechnology Fund1.61%
Select Health Care Portfolio1.32%
T. Rowe Price Health Sciences Fund, Inc.1.31%
Strategic Advisers Fidelity U.S. Total Stock Fund1.23%
T. Rowe Price New Horizons Fund, Inc.1.22%
Select Biotechnology Portfolio1.15%
Fidelity Small Cap Growth Fund1.15%

OakChart. VRDN. Cached 15 minutes.